Creative Financial Designs’s Fulcrum Therapeutics FULC Stock Holding History

Creative Financial Designs’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7	Buy	+2	New	+$8	﹤0.01%	2361

Other funds holding FULC

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Bessemer Group Woodbridge, New Jersey $72.8B AUM 32.97% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

Creative Financial Designs's FULC Position: Q3 2026 in Review

Creative Financial Designs opened a new position in Fulcrum Therapeutics (FULC) in Q3 2026: 2 shares worth $7. The stake represents ﹤0.01% of the portfolio and ranks #2361 among its holdings.

56 funds tracked by Wall St. Rank hold FULC as of Q3 2026.

Creative Financial Designs held 2 shares of Fulcrum Therapeutics worth $7 as of Q3 2026.
Fulcrum Therapeutics was a new Creative Financial Designs position in Q3 2026.
Fulcrum Therapeutics made up ﹤0.01% of Creative Financial Designs's portfolio in Q3 2026, its #2361 holding.
56 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q3 2026.

Based on Creative Financial Designs's 13F filing for Q3 2026, filed 4 Nov 2026.